amodiaquine has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, BS; Han, M; Jeong, I; Kim, CH; Kim, DJ; Kim, KS; Kim, WG; Lee, EH; Moon, J; Naffin-Olivos, JL; Nguyen, QT; Park, CH; Petsko, GA; Rajan, S; Ringe, D; Shin, J; Sohn, M; Tu, Y; Yoon, HS | 1 |
| Abdulrahman, AA; Chengcheng, M; Gao, D; Jiao, W; Kambey, PA; Kanwore, K; Nadeem, I; Xiaoxiao, G | 1 |
2 other study(ies) available for amodiaquine and oxidopamine
| Article | Year |
|---|---|
Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease.
Topics: Amodiaquine; Animals; Behavior, Animal; Chloroquine; Disease Models, Animal; Ligands; Neurogenesis; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinson Disease; Rats | 2015 |
The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway.
Topics: Amodiaquine; Animals; Brain; Enzyme Inhibitors; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; p38 Mitogen-Activated Protein Kinases; Parkinsonian Disorders; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction | 2021 |